GLP1R and medullary thyroid gland carcinoma: Moreover, cardiovascular outcome trials for GLP‐1 receptor agonists demonstrated stable calcitonin levels in patients over 3 years of drug exposure, with no observed increase in the risk of newly diagnosed medullary thyroid carcinomas [26].